Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SON-1010 + atezolizumab
- Development stage
- Unknown
- Lead developer
- Sonnet BioTherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intravenous
01
Overview
**SON-1010 + atezolizumab** is an investigational combination therapy that pairs SON-1010, a recombinant immunotherapeutic drug composed of unmodified single-chain human interleukin-12 (IL-12) fused to an albumin-binding domain of a single-chain antibody fragment (A10m3), with atezolizumab, a PD-L1 checkpoint inhibitor monoclonal antibody (marketed as Tecentriq). SON-1010 is designed to prolong circulation and target the tumor microenvironment (TME) by hitchhiking on human serum albumin (HSA), thus enhancing delivery of IL-12 to tumors. The combination aims to synergistically activate immune responses—SON-1010 stimulating interferon gamma (IFNγ) and immune cell activation, and atezolizumab relieving PD-L1-mediated inhibition—potentially resulting in improved tumor control in patients with advanced solid tumors, particularly platinum-resistant ovarian cancer (PROC) and other advanced malignancies[1][2][3][4][5].
- Brand names
- Tecentriq
- Other names
- SON-1010 + Tecentriq
02
Targets
IL-12R (Interleukin-12 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on SON-1010 + atezolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SON-1010 + atezolizumab.